Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, University of Sydney, NSW, Australia.
Gynecol Oncol. 2019 Mar;152(3):465-471. doi: 10.1016/j.ygyno.2018.12.019.
Australia's HPV vaccination and HPV-based cervical screening programs are changing the landscape in cervical cancer prevention. We aim to identify areas which can make the biggest further impact on cervical cancer burden. This protocol describes the first stage of a program of work called Pathways-Cervix that aims to generate evidence from modelled evaluations of interventions across the cervical cancer spectrum.
Based on evidence from literature reviews and guidance from a multi-disciplinary Scientific Advisory Committee (SAC), the most relevant evaluations for prevention, diagnosis and treatment were identified.
Priority evaluations agreed by the SAC included: increasing/decreasing and retaining vaccination uptake at the current level; vaccinating older women; increasing screening participation; methods for triaging HPV-positive women; improving the diagnosis of cervical intraepithelial neoplasia (CIN) and cancer; treating cervical abnormalities and cancer; and vaccinating women treated for CIN2/3 to prevent recurrence. Evaluations will be performed using a simulation model, Policy1-Cervix previously used to perform policy evaluations in Australia. Exploratory modelling of interventions using idealised scenarios will initially be conducted in single birth cohorts. If these have a significant impact on findings then evaluations with more realistic assumptions will be conducted. Promising strategies will be investigated further by multi-cohort simulations predicting health outcomes, resource use and cost outcomes.
Pathways-Cervix will assess the relative benefits of strategies and treatment options in a systematic and health economic framework, producing a list of 'best buys' for future decision-making in cervical cancer control.
澳大利亚的 HPV 疫苗接种和 HPV 为基础的宫颈癌筛查计划正在改变宫颈癌预防的格局。我们旨在确定可以对宫颈癌负担产生最大影响的领域。本方案描述了名为“Pathways-Cervix”的工作计划的第一阶段,该计划旨在通过对宫颈癌谱内干预措施的建模评估来生成证据。
基于文献综述的证据和多学科科学咨询委员会(SAC)的指导,确定了最相关的预防、诊断和治疗评估。
SAC 同意的优先评估包括:提高/降低并保持当前水平的疫苗接种率;为老年妇女接种疫苗;增加筛查参与率;对 HPV 阳性妇女进行分类的方法;改善宫颈癌前病变和癌症的诊断;治疗宫颈异常和癌症;以及为接受 CIN2/3 治疗的妇女接种疫苗以预防复发。将使用 Policy1-Cervix 模拟模型进行评估,该模型以前在澳大利亚用于进行政策评估。最初将在单一生育队列中对干预措施进行理想化情景的探索性建模。如果这些对研究结果有重大影响,则将进行更符合实际假设的评估。有前途的策略将通过预测健康结果、资源使用和成本结果的多队列模拟进一步进行调查。
Pathways-Cervix 将在系统和健康经济框架内评估策略和治疗选择的相对益处,为宫颈癌控制的未来决策制定提供“最佳购买”清单。